CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Regulation FD DisclosureITEM 7.01
Regulation FD Disclosures
CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Regulation FD Disclosure
On November 29, 2016, CytRx Corporation (“we,” “us,” “our” and the “company”) issued a press release announcing updated results from our pivotal Phase 3 trial of aldoxorubicin as a treatment for patients with second line soft-tissue sarcomas. A copy of the press release is attached as Exhibit 99.1 to this Report and incorporated herein by reference.
Also on November 29, 2016, we hosted a webcast to discuss the top-line results. A replay of the webcast will be posted on our website at www.cytrx.com.
The information in this Item 7.01 and Exhibit 99.1 to this Report shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
See the Exhibit Index which immediately follows the page thereof and is incorporated herein by reference.
About CYTRX CORPORATION (NASDAQ:CYTR)
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology. CYTRX CORPORATION (NASDAQ:CYTR) Recent Trading Information
CYTRX CORPORATION (NASDAQ:CYTR) closed its last trading session down -0.008 at 0.558 with 893,995 shares trading hands.
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology. CYTRX CORPORATION (NASDAQ:CYTR) Recent Trading Information
CYTRX CORPORATION (NASDAQ:CYTR) closed its last trading session down -0.008 at 0.558 with 893,995 shares trading hands.